Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Pancreatic Cancer Treatment
100%
Small Molecules
100%
Gemcitabine
100%
Pancreatic Ductal Adenocarcinoma
90%
Pancreatic Duct Cells
36%
Tumor Growth
18%
BxPC-3
18%
PANC-1
18%
Tumor Metastasis
18%
In Vivo Pharmacokinetics
18%
Inhibit Tumor
9%
Chemotherapy
9%
Necropsy
9%
Efficacy Study
9%
Successful Outcome
9%
Nude Mouse Model
9%
Extensive Structure
9%
Colon Cancer
9%
Current Therapies
9%
Combinatorial Approach
9%
Tumor Cells
9%
Pharmacokinetics
9%
Clinical Trials
9%
Caspase-dependent Apoptosis
9%
Xenograft Model
9%
Therapeutic Effect
9%
Adenocarcinoma Cells
9%
MIA PaCa-2
9%
Structure-activity Relationship Studies
9%
Maximum Tolerated Dose
9%
Xenograft Mouse Model
9%
Athymic nude Mice
9%
Orally Bioavailable
9%
Oral Dose
9%
Combination Treatment
9%
Mechanism of Action
9%
In Situ
9%
In Vivo Imaging
9%
Pro-survival
9%
Systemic Toxicity
9%
G1 Cell Cycle Arrest
9%
Metastasis
9%
Molecular Targets
9%
Therapeutic Index
9%
RB Pathway
9%
Dose-response
9%
Cell Viability
9%
Study Support
9%
Standard of Care
9%
Gemcitabine-resistant
9%
Cancer Xenograft
9%
Specific Aims
9%
Inhibit Growth
9%
Metastatic Pancreatic Ductal Adenocarcinoma
9%
Drug-likeness
9%
Apoptosis Induction
9%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
Pancreas Adenocarcinoma
100%
Gemcitabine
80%
Tumor Growth
13%
Mouse Model
13%
Pharmacodynamics
13%
Therapeutic Effect
6%
Efficacy Study
6%
Clinical Trial
6%
Pharmacokinetics
6%
Nude Mouse
6%
Neoplasm
6%
Caspase
6%
Maximum Tolerated Dose
6%
Cell Viability
6%
Colon Carcinoma
6%
Therapeutic Window
6%
Cuniculidae
6%
Tumor Necrosis Factor
6%
Molecular Target
6%
Structure Activity Relationship
6%
Chemotherapy Regimens
6%